Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results from the NAPLS Project

Schizophrenia Bulletin

Volumn 41, Issue 2, 2015, Pages 419-428

  Perkins, Diana O ^a   Jeffries, Clark D ^b   Addington, Jean ^c   Bearden, Carrie E ^d   Cadenhead, Kristin S ^e   Cannon, Tyrone D ^f,g   Cornblatt, Barbara A ^h   Mathalon, Daniel H ⁱ   McGlashan, Thomas H ^g   Seidman, Larry J ^j   Tsuang, Ming T ^e   Walker, Elaine F ^k   Woods, Scott W ^g   Heinssen, Robert ^l  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f YALE UNIVERSITY   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ZUCKER HILLSIDE HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k EMORY UNIVERSITY   (United States)

^l NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

more..

Author keywords

clinical high risk; immune; inflammation; malondialdehyde modified low density lipoprotein (MDA LDL); multiplex; oxidative stress; prodrome; psychosis; risk prediction

Indexed keywords

APOLIPOPROTEIN D; BLOOD CLOTTING FACTOR 7; GROWTH HORMONE; HYDROCORTISONE; IMMUNOGLOBULIN E; INTERLEUKIN 1BETA; INTERLEUKIN 7; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MATRILYSIN; RESISTIN; STEM CELL FACTOR; THYROTROPIN;

ADULT; ARTICLE; BLOOD EXAMINATION; CLASSIFIER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; BLOOD; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM; PHYSIOLOGY; PRODROMAL SYMPTOM; RISK ASSESSMENT; YOUNG ADULT;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; MALE; OXIDATIVE STRESS; PITUITARY-ADRENAL SYSTEM; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; RISK ASSESSMENT; YOUNG ADULT;

EID: 84940845088     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu099     Document Type: Article

References (58)

1. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785-1804.
2. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69:220-229.
3. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65:28-37.
4. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35:894-908.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association Press; 2013.
6. Carpenter WT, Tandon R. Psychotic disorders in DSM-5: summary of changes. Asian J Psychiatr. 2013;6:266-268.
7. Tsuang MT, Van Os J, Tandon R, et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res. 2013;150:31-35.
8. Meehl PE, Rosen A. Antecedent probability and the efficiency of psychometric signs, patterns, or cutting scores. Psychol Bull. 1955;52:194-216.
9. Anderson G, Berk M, Dodd S, et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:1-4.
10. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74:400-409.
11. Walker EF, Trotman HD, Pearce BD, et al. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry. 2013;74:410-417.
12. Schwarz E, van Beveren NJ, Ramsey J, et al. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr Bull. 2014;40:787-795.
13. Schwarz E, Guest PC, Rahmoune H, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17:494-502.
14. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39:1174-1179.
15. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663-671.
16. Addington J, Cadenhead KS, Cornblatt BA, et al. North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res. 2012;142:77-82.
17. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863-865.
18. First MB, Spitzer RL, Givvon M, Williams JBW. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Nonpatient Edition (SCID-I/NP). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
19. Müller MJ, Brening H, Gensch C, Klinga J, Kienzle B, Müller KM. The Calgary Depression Rating Scale for schizophrenia in a healthy control group: psychometric properties and reference values. J Affect Disord. 2005;88:69-74.
20. Knight RG, Waal-Manning HJ, Spears GF. Some norms and reliability data for the State-Trait Anxiety Inventory and the Zung Self-Rating Depression scale. Br J Clin Psychol. 1983;22 (Pt 4):245-249.
21. Drake RE, Mueser KT, McHugo GJ. Clinician rating scale: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). In: Sederer LI, Dickey B, eds. Outcomes Assessment in Clinical Practice. Baltimore, MD: Williams and Wilkins; 1996:113-116.
22. Cadenhead KS, Addington J, Cannon T, et al. Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry. 2010;4:220-226.
23. Woods SW, Addington J, Bearden CE, et al. Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. Schizophr Res. 2013;148:99-104.
24. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty T, Gangadhar BN. Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res. 2010;119:131-137.
25. Mukhopadhyay P, Rajesh M, Horváth B, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/ nitrative stress, and cell death. Free Radic Biol Med. 2011;50:1368-1381.
26. Sarafian TA, Magallanes JA, Shau H, Tashkin D, Roth MD. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol. 1999;20:1286-1293.
27. Ranganathan M, Braley G, Pittman B, et al. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology (Berl). 2009;203:737-744.
28. Vargas HO, Nunes SO, de Castro MR, et al. Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neurosci Lett. 2013;544:136-140.
29. Hruškovičová H, Dušková M, Simůnková K, et al. Effects of smoking cessation on hormonal levels in men. Physiol Res. 2013;62:67-73.
30. Míguez MJ, Rosenberg R, Burbano-Levy X, Carmona T, Malow R. The effect of alcohol use on IL-6 responses across different racial/ethnic groups. Future Virol. 2012;7:205-213.
31. Schrieks IC, van den Berg R, Sierksma A, Beulens JW, Vaes WH, Hendriks HF. Effect of red wine consumption on biomarkers of oxidative stress. Alcohol Alcohol. 2013;48:153-159.
32. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
33. Zaiontz C. Real Statistics Using Excel. http://www.real-statistics. com/. Accessed January 26, 2014.
34. Liu X, Krishnan A, Mondry A. An entropy-based gene selection method for cancer classification using microarray data. BMC Bioinformatics. 2005;6:76.
35. Hand DJ. Classifier technology and the illusion of progress. Statistical Science. 2006;21:1-34.
36. Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012;98:691-698.
37. Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98:683-690.
38. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proc Fourteenth Intl Joint Conf Artif Intell. 1995;12:1137-1143.
39. Tropsha A. Best Practices for QSAR model development, validation, and exploitation. Mol Inform. 2010;29:476-488.
40. Leidinger P, Keller A, Borries A, et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer. 2010;10:262.
41. Hand DJ. Evaluating diagnostic tests: The area under the ROC curve and the balance of errors. Stat Med. 2010;29:1502-1510.
42. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
43. Lindgren F, Hansen B, Karcher W, Sjostrom M, Eriksson L. Model validation by permutation tests. Journal of Chemometrics 1996;10:521-532.
44. Smit S, Hoefsloot HC, Smilde AK. Statistical data processing in clinical proteomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;866:77-88.
45. Ramsey JM, Schwarz E, Guest PC, et al. Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One. 2013;8:e78729.
46. Schwarz E, Guest PC, Rahmoune H, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2011;17:1-9.
47. Schwarz E, Guest PC, Rahmoune H, et al. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World J Biol Psychiatry. 2012;13:627-632.
48. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014;40:120-131.
49. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316-328.
50. Ganfornina MD, Do Carmo S, Lora JM, et al. Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell. 2008;7:506-515.
51. Walker EF, Cornblatt BA, Addington J, et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res. 2009;115:50-57.
52. Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. Biol Psychiatry. 2000;47:762-766.
53. Guest PC, Schwarz E, Krishnamurthy D, et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011;36:1092-1096.
54. Goldstein JM, Seidman LJ, Makris N, et al. Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry. 2007;61:935-945.
55. Nordholm D, Krogh J, Mondelli V, Dazzan P, Pariante C, Nordentoft M. Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis. Psychoneuroendocrinology. 2013;38:2394-2404.
56. Walder DJ, Trotman HD, Cubells JF, Brasfield J, Tang YL, Walker EF. Catechol-O-methyltransferase modulation of cortisol secretion in psychiatrically at-risk and healthy adolescents. Psychiatr Genet. 2010;20:166-170.
57. Walker EF, Brennan PA, Esterberg M, Brasfield J, Pearce B, Compton MT. Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth. J Abnorm Psychol. 2010;119:401-408.
58. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107-120.